Abbott
-
Abbott honored with Asian CSR award for leadership in science education
Abbott science education programs advance science learning for children in Asia and around the world.
Abbott | 24 October 2011
-
Abbott named to Dow Jones Sustainability Indexes for seventh consecutive year
Receives recognition of leading corporate citizenship performance.
Abbott | 09 September 2011
-
Abbott receives FDA approval for ALK gene test for lung cancer therapy selection
Abbott announced it has received approval from the US Food and Drug Administration (FDA) for a new molecular diagnostic test designed to detect rearrangements of the anaplastic lymphoma kinase (ALK) gene in non-small-cell lung cancer (NSCLC). The new…
Abbott | 27 August 2011
-
Abbott receives FDA approval for Lupron Depot-PED for treatment of CPP
Two new strengths in a three-month formulation expand Lupron Depot-PED dosing options for children with CPP.
Abbott | 17 August 2011
-
Abbott introduces vector-borne pathogen test to detect microorganisms carried by insects
Abbott's Ibis Biosciences has introduced a new molecular assay to detect a wide variety of vector-borne microorganisms, including those known to cause Lyme Disease, Rocky Mountain Spotted Fever, Babesiosis, Ehrlichiosis and Anaplasmosis. Vector-borne…
Abbott | 10 August 2011
-
Biogen Idec, Abbott report positive results from trial of daclizumab HYP
Biogen Idec and Abbott announced positive top-line results from SELECT, a global, registrational phase 2b clinical trial designed to evaluate the investigational compound daclizumab high-yield process (DAC HYP) in people with relapsing-remitting mult…
Abbott | 09 August 2011
-
Abbott, Biotest to develop novel antibody for autoimmune diseases
BT-061 in clinical development for the treatment of RA and psoriasis
Abbott | 21 June 2011
-
Reata, Abbott initiate global phase 3 study of bardoxolone methyl
Reata Pharmaceuticals Inc and Abbott announced the initiation of a pivotal phase 3 clinical trial to evaluate the safety and efficacy of bardoxolone methyl in patients with chronic kidney disease (eGFR of 15-29 mL/min/1.73 m2) and type 2 diabetes. …
Abbott | 17 June 2011
-
Abbott reports interim phase 3 results of advanced Parkinson's treatment
In a 54-week study, after 12 weeks of treatment with levodopa-carbidopa intestinal gel, patients reported improvement in motor symptoms.
Abbott | 09 June 2011
-
Abbott statement on interim study results of AIM-HIGH
The National Heart, Lung and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH), disclosed results from an interim analysis of the AIM-HIGH clinical trial. AIM-HIGH was designed to test whether raising HDL and lowering …
Abbott | 26 May 2011
